Contribution to More Patient-Friendly ART Treatment: Efficacy of Continuous Low-Dose GnRH Agonist as the Only Luteal Support—Results of a Prospective, Randomized, Comparative Study

<table class="figure-group"><tr class="fig-image" id="a"><td><object data="https://static.hindawi.com/articles/ije/volume-2015/727569/figures/727569.fig.002a.svgz" name="727569.fig.002a" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(a) </b>Mean serum P4 levels</td></tr><tr class="fig-image" id="b"><td><object data="https://static.hindawi.com/articles/ije/volume-2015/727569/figures/727569.fig.002b.svgz" name="727569.fig.002b" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(b) </b>Mean serum E2 levels</td></tr><tr class="fig-image" id="c"><td><object data="https://static.hindawi.com/articles/ije/volume-2015/727569/figures/727569.fig.002c.svgz" name="727569.fig.002c" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(c) </b>Mean serum LH levels</td></tr></table>

<div>Hormone levels during the luteal phase on D0 (day of ovulation trigger), D2, D5, D9, and D14. (a) Mean progesterone levels. (b) Mean estradiol levels. (c) Mean LH levels.</div>

International Journal of Endocrinology

fig2

Figure 2

Figure 2: Contribution to More Patient-Friendly ART Treatment: Efficacy of Continuous Low-Dose GnRH Agonist as the Only Luteal Support—Results of a Prospective, Randomized, Comparative Study 

Figure 2 | Contribution to More Patient-Friendly ART Treatment: Efficacy of Continuous Low-Dose GnRH Agonist as the Only Luteal Support—Results of a Prospective, Randomized, Comparative Study 